Company intelligence / Profile preview
SynuSight Biotech
Shanghai, Shanghai, China
- Ownership
- Private
- Development stage
- Other
01
Overview
SynuSight Biotech has successfully completed investigator-initiated trials (IIT) for its lead candidate 18F-FD4, a first-in-class PET tracer for alpha-synuclein. Results demonstrated excellent blood-brain barrier penetration and high specificity in patients with Parkinson's disease and multiple system atrophy. The company is advancing the program into registration-enabling Phase 1 trials in the U.S. and China.
- Therapeutic areas
- Neurology
- Modalities
- RadiopharmaceuticalSmall molecule
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
ABLi TherapeuticsXingImagingThe Michael J. Fox Foundation
Beyond the preview
Go deeper on SynuSight Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SynuSight Biotech.